Enanta Pharmaceuticals Inc ENTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
-
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
-
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
-
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
-
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
-
Enata Sues Pfizer in European Union Over Paxlovid Covid-19 Drug — Update
-
Enata Sues Pfizer Over Paxlovid Covid-19 Drug
Trading Information
- Previous Close Price
- $13.16
- Day Range
- $12.90–13.60
- 52-Week Range
- $6.45–17.15
- Bid/Ask
- $13.52 / $13.62
- Shares Outstanding
- 29.08M
- Market Cap
- $395.47M
- Volume/Avg
- 21,731 / 212,434
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.99
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 120
- Website
- https://www.enanta.com
Valuation
|
Metric
|
ENTA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.28 |
Price/Sales | 4.78 |
Price/Cash Flow | — |
Price/Earnings
ENTA
Financial Strength
|
Metric
|
ENTA
|
|---|---|
Quick Ratio | 3.69 |
Current Ratio | 3.84 |
Interest Coverage | −5.80 |
Quick Ratio
ENTA
Profitability
|
Metric
|
ENTA
|
|---|---|
Return on Assets (Normalized) | −15.99% |
Return on Equity (Normalized) | −51.51% |
Return on Invested Capital (Normalized) | −31.41% |
Return on Assets
ENTA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&JntVxz | LOCK|fB#> | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|X^t%GM> | LOCK|T<rk! | $70B | |||
| argenx SE ADR
ARGX
| LOCK|$J$Y@Jh | LOCK|$R% | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|s<>MFk | LOCK|#> | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|vBq@kr^ | LOCK|@ZHR% | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|JY>D%R# | LOCK|T<Ny | $25B | |||
| Moderna Inc
MRNA
| LOCK|TSS??% | LOCK|q>> | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|H&G?!QG | LOCK|?&P | $23B | |||
| Incyte Corp
INCY
| LOCK|%YsSy! | LOCK|<vw | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|$d%^W!Q | LOCK|YWd | $16B |
United States